Clinical Trials · NCT00242541

Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas

Name: Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 4Octreotide

Phase: Phase 4
Recruitment status: Terminated
Sponsor: Novartis Pharmaceuticals
Enrollment: 50
Start date: Mar 2003
Locations: 1 site, Mexico
Primary endpoint: To evaluate the use of octreotide acetate to reduce levels of GH and IGF-I in Acromegalic patients with micro (< 10 mm) and macroadenomas (> 10 mm)

View Octreotide compound reference